Sglt2 Inhibitors as Cardioprotective Agents Beyond Diabetes
DOI:
https://doi.org/10.31149/ijimm.v4i2.2670Keywords:
SGLT2 inhibitors, heart failure, cardiovascular outcomes, non-diabetic individuals, cardiorenal axis.Abstract
Sodium-glucose cotransporter-2 (SGLT2) inhibitors were first used to lower blood
glucose in type 2 diabetes. Nevertheless, increasing data from heart failure–specific trials and from large
cardiovascular outcome trials have proven that the favorable effects of SGLT2 inhibitors are not related
to their glucose-lowering effect. These drugs have consistently been shown to reduce rates of
hospitalization for heart failure, cardiovascular mortality, and progression of renal disease in both
diabetic and non-diabetic patients. Retrospective review summarizes up-to-date evidence of SGLT2
inhibitors in reducing the risk of heart failure. The purpose of this article is to present recent research
articles on benefits, mechanisms, major clinical trials, and near-term practical applications that are
pertinent to current cardiovascular care. Knowledge of these pleiotropic effects is crucial for identifying
the optimal candidates and integrating SGLT2 inhibitors into routine cardiology practice
References
1. Zinman B, wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in
type 2 diabetes. N Engl J Med. 2015; 373:2117-2128.
2. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type
2 diabetes. N Engl J Med. 2017; 377:644-657.
3. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes.
N Engl J Med. 2019; 380:347-357.
4. McMurray JJV, Solomon SD, Inzucchi SE, et al. Dapagliflozin in patients with heart failure and
reduced ejection fraction. N Engl J Med. 2019; 381:1995-2008.
5. Packer M, Anker SD, Butler J, et al. Cardiovascular and renal outcomes with empagliflozin in heart
failure. N Engl J Med. 2020; 383:1413-1424.
6. Solomon SD, McMurray JJV, Claggett B, et al. Dapagliflozin in heart failure with preserved ejection
fraction. N Engl J Med. 2022; 387:1089-1098.
7. Zelniker TA, Wiviott SD, Raz I, et al. SGLT2 inhibitors for primary and secondary prevention of
cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of
cardiovascular outcome trials. Lancet. 2019; 393:31-39.
8. McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of
acute and chronic heart failure. Eur Heart J. 2021; 42:3599-3726.
9. . Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. Dapagliflozin in patients with chronic kidney
disease. N Engl J Med. 2020; 383:1436-1446.
10. Butler J, Zannad F, Filippatos G, et al. Cardiovascular effects of SGLT2 inhibitors in heart failure:
mechanisms and clinical implications. Nat Rev Cardiol. 2022; 19:279-294.
11. Bhatt DL, Szarek M, Steg PG, et al. Sotagliflozin in patients with diabetes and recent worsening
heart failure. N Engl J Med. 2021; 384:117-128.
12. Verma S, McMurray JJV. SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of
the-art review. Diabetology. 2018; 61:2108-2117.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 International Journal of Integrative and Modern Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
